Cidara Therapeutics is focused on developing targeted immunotherapies that aim to enhance patient outcomes for those suffering from serious diseases. Central to their approach is the Cloudbreak platform, which enables the creation of "single molecule cocktails." This innovative technology combines targeted small molecules and peptides with a human antibody fragment (Fc), resulting in drug-Fc conjugates (DFCs). These DFC immunotherapies are designed to specifically inhibit disease targets while also engaging the immune system, thereby providing a dual mechanism of action that could lead to more effective treatments.

The company's development pipeline showcases a range of new therapeutic strategies that seek to transform current treatment and prevention methods. By leveraging the capabilities of their proprietary Cloudbreak platform, Cidara is working on DFCs that target various serious conditions, including influenza and cancers. This approach not only aims to improve the efficacy of existing therapies but also to provide innovative solutions for diseases that currently have limited treatment options.

United States

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

Cancer

Infectious Diseases

Cidara Therapeutics

Candidemia

Fungal infections

Infectious disease

<p class="font_7">Rezafungin is a novel echinocandin antifungal and the only once-weekly drug candidate being developed for the first-line treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.</p>

REZZAYO (Rezafungin)

Rezafungin

Influenza

<p class="font_7">CD388, the lead flu DFC, to achieve universal prevention of seasonal and pandemic influenza with a single dose. Drug-Fc conjugates are not vaccines or monoclonal antibodies. Their targeting domains are small molecule antivirals that bind to a highly conserved target on the influenza cell surface, which is essential for viral proliferation and enables universal influenza coverage. These long-acting, bispecific DFCs are designed to directly inhibit viral proliferation while simultaneously directing immune-mediated clearance of the virus. The two distinct and complementary mechanisms are designed to maximize antiviral activity of DFCs.</p>

Cidara Therapeutics

Company Details